Clinical Trial

A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A randomized, double-blinded, positive-controlled clinical trial will be conducted to observe the safety and immunogenicity of DX-104 in adults 18 to 50 years of age.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-04-07
notable Primary completion moved earlier: 2027-05-31 -> 2027-05-01 2026-04-07
minor Completion pushed: 2027-05-31 -> 2027-07-01 2026-04-07
Trial Details
NCT Number NCT07395739
Lead Sponsor Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)
Conditions Neisseria Meningitidis Serogroup B
Enrollment 30 participants
Start Date 2026-03-20
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-06